Turning Point Therapeutics and Almac Diagnostic Services recently announced approval by the US Food and Drug Administration of an investigational device exemption for use of an Almac diagnostic assay to determine......

PrediLife said recently that it has signed on the Institut Curie to perform the genetic analysis portion of its MammoRisk breast cancer risk assay.

Qiagen reported after the close of the market recently that its first quarter revenues grew nearly 2 percent year over year as the firm fell short of analysts' topline estimates but beat expectations on the bottom line.

Biocartis announced it has entered into an agreement with AstraZeneca.

Becton Dickinson said today that the US Food and Drug Administration has granted 510(k) clearance for its BD Max enteric viral panel, a molecular diagnostic test for the detection and differentiation of pathogens that cause viral gastroenteritis.

Siemens Healthineers (Erlangen, Germany) has entered into a strategic partnership with Australian integrated healthcare provider Primary Health Care to deploy more than 70 Atellica Solution immunoassay and clinical chemistry analyzers,

December 22nd 2018 was Winter Solstice. Ancient Chinese believed that Yangqi (positive or muscular things) will become stronger and stronger after this day and a new life cycle begins, so it should be celebrated as an auspicious day.

Sysmex and MolecularMD have signed a non-exclusive collaboration agreement focused on the development and commercialization of companion diagnostics for precision medicine.

Greiner Bio One International (Kremsmünster, Ober?sterreich, Austria) has launched the innovative VACUETTE SAFELINK tube holder with male luer lock that facilitates quick and easy blood collection.

The global point of care (POC) urinalysis market is projected to grow at a CAGR of more than 3% over the 2018-2022 period,

Danaher today initiated its earning outlook for 2019, saying EPS is anticipated to be in the range of $4.02 to $4.12.

Recently, Sansure Biotech and Thermo Fisher Scientific (hereinafter referred to as: Thermo Fisher) signed a strategic cooperation agreement.

GenMark Diagnostics announced recently it has received 510(k) clearance from the US Food and Drug Administration for a molecular diagnostic panel assay to detect fungal pathogens from blood cultures of patients with suspected blood stream infections.

Recently AmoyDx ROS1 gene fusion detection kit (fluorescence PCR method) was approved by Taiwan Food and Drug Administration（TFDA).

Foundation Medicine announced recently that its FoundationOne CDx genomic profiling assay has received regulatory approval from Japan's Ministry of Health, Labour and Welfare (MHLW).